While peginterferon beta-1a dosed every 4 weeks also had a significant effect on the clinical endpoints, the reduction relative to placebo in ARR and magnetic resonance imaging (MRI) endpoints was numerically greater in the every 2 weeks dosing group compared with the every 4 weeks dosing group.
These results suggested that neopterin and the monthly cumulative duration of IFN pharmacological activity of the every 2 weeks dosing group is therefore doubled relative to the every 4 weeks dosing group.
Median monthly cumulative EAUC 0,336 h) was 1912 ng ml−1 h for the every 2 weeks dosing group and 1397 ng ml−1 h for the every 4 weeks dosing group, based on week 24 data assuming steady-state.
For each drug dosing group, animals were dosed IT once daily with 100 μL nanosuspension formulations to deliver the desired doses for a period of 6 days (total 6 doses).
Descriptive statistics for PK parameters were summarised by dosing group, day and cycle.
In glibenclamide (10 mg/kg) dosing group, no significant changes compared to that of diabetic control were detected.
The neopterin response decreased over time in the present study (week 4 vs. week 24), especially in the peginterferon beta-1a every 2 weeks dosing group.
Unlike PK profiles, which did not change over time, the magnitude of neopterin elevation decreased over time for the every 2 weeks dosing group.
In the 5 mg donepezil dosing group, two patients (#13 and #23) out of three were undersupplied during certain time periods.
The Epeak and EAUC 0,336 h) of the every 2 weeks dosing group decreased by 40% and 48%, respectively, from week 4 to week 24.
The number or proportion of patients with overall best response of CR was compared for each pegloticase dosing group versus the placebo group using Fisher's exact test.
